Longevity medicine practice, while bearing some commonalities and overlap with lifestyle medicine, functional medicine, preventative, and precision medicine, has been envisaged as a new discipline and longevity clinics and centers have flourished. Its distinctive features include a foundation in aging biology (geroscience), the application of model organism insights to patients at an earlier stage, and full deployment of technology and biomarkers of healthy aging towards health surveillance, risk mitigation and early detection and intervention. These approaches target not only ameliorating and preventing disease states, but also a healthy longevity blueprint whereby biological aging is slowed, functional decline ameliorated or partially reverted, and healthspan and performance trajectories are optimized. Longevity medicine is presently undergoing a transformation toward medicine 3.0 health paradigms leveraging new diagnostic and therapeutic technological approaches. Despite these advances, both opportunities and challenges remain for identifying and monitoring biological aging as target. In the laboratory, a number of therapies have reliably demonstrated lifespan extension in model organisms. Yet there are no clinically proven FDA-approved therapies targeting our aging trajectory. At the next 2024 Longevity Med Summit Dr. Barzilai will discuss the latest insights into promising longevity therapeutics directly from the most up-to-date cutting edge foundational and translational research. By understanding these findings, including knowns and unknowns, practitioners and centers in longevity medicine are better equipped to incorporate and apply new insights and discoveries towards better healthspan for their patients and clients.